{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:38:01Z","timestamp":1792017481900,"version":"4.4.0"},"reference-count":310,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0119700"],"award-info":[{"award-number":["2022YFE0119700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.drup.2025.101286","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:10:53Z","timestamp":1753974653000},"page":"101286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy"],"prefix":"10.1016","volume":"83","author":[{"given":"Feifeng","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-3438","authenticated-orcid":false,"given":"Bold","family":"Sharavyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Naranmandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-029X","authenticated-orcid":false,"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2025.101286_bib1","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2017.82","article-title":"The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16-1 expression","volume":"31","author":"Abraham","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.celrep.2019.03.009","article-title":"The hematopoietic oxidase NOX2 regulates Self-Renewal of leukemic stem cells","volume":"27","author":"Adane","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2025.101286_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2025.101286_bib4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1186\/s12885-015-1695-x","article-title":"Enhancing SHP-1 expression with 5-azacytidine May inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia","volume":"15","author":"Al-Jamal","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib5","article-title":"BiTEs, DARTS, BiKEs and TriKEs-Are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.drup.2025.101286_bib6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib7","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2025.101286_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.588876","article-title":"Emergence of BCR-ABL1 fusion in AML Post-FLT3 Inhibitor-Based therapy: a potentially targetable mechanism of resistance - a case series","volume":"10","author":"Alotaibi","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib9","article-title":"AML-162: efficacy and safety of venetoclax in combination with gilteritinib for Relapsed\/Refractory FLT3-Mutated acute myeloid leukemia: updated analyses of a phase 1b study","volume":"21","author":"Altman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.drup.2025.101286_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib11","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","article-title":"Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3","volume":"101","author":"Amico","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib13","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib14","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1182\/blood-2021-153927","article-title":"Developing a safer Anti-CD44v6 chimeric antigen receptor t cell against hematological cancers by mitigating on-Target Off-Tumor toxicity","volume":"138","author":"Awuah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/bloodadvances.2021004611","article-title":"Momelotinib is a highly potent inhibitor of FLT3-mutant AML","volume":"6","author":"Azhar","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","article-title":"Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia","volume":"36","author":"Baccelli","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543784.2022.2032642","article-title":"Prospect of CAR T-cell therapy in acute myeloid leukemia","volume":"31","author":"Badar","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.drup.2025.101286_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-11-056838","article-title":"Pairing SOCS with CD33","volume":"109","author":"Ball","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baragano Raneros","year":"2015","journal-title":"Genes Immun."},{"key":"10.1016\/j.drup.2025.101286_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"Berg, the interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib21","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","article-title":"Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib22","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2352-3026(24)00034-6","article-title":"Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib23","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/bloodadvances.2019001068","article-title":"LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML","volume":"3","author":"Beeharry","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib24","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/ajh.25943","article-title":"Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients","volume":"95","author":"Borthakur","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drup.2025.101286_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14712598.2011.543895","article-title":"Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy","volume":"11","author":"Breccia","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2025.101286_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41568-019-0132-x","article-title":"Targeting chromatin complexes in fusion protein-driven malignancies","volume":"19","author":"Brien","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib31","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-Specific CAR t cells: a First-in-Human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib35","first-page":"2059","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013"},{"key":"10.1016\/j.drup.2025.101286_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fonc.2020.00127","article-title":"DNA-PK inhibitor, M3814, as a new combination partner of mylotarg in the treatment of acute myeloid leukemia","volume":"10","author":"Carr","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib37","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted t cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2025.101286_bib39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/leu.2015.346","article-title":"The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3\/ITD acute myeloid leukemia cells","volume":"30","author":"Chang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41375-019-0582-x","article-title":"In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site","volume":"34","author":"Chaturvedi","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2025.101286_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00387","article-title":"CD33_PGx6_Score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: a report from the children's oncology group","author":"Chauhan","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib45","doi-asserted-by":"crossref","first-page":"47018","DOI":"10.18632\/oncotarget.10147","article-title":"Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2025.101286_bib46","article-title":"Identification of new IDH2(R140Q) inhibitors by discriminatory analysis-based molecular docking and biological evaluation","volume":"354","author":"Chen","year":"2021","journal-title":"Arch. Pharm. (Weinh. )"},{"key":"10.1016\/j.drup.2025.101286_bib47","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107540","article-title":"GDE2-Dependent activation of canonical wnt signaling in neurons regulates oligodendrocyte maturation","volume":"31","author":"Choi","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2025.101286_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101286_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib51","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.drup.2025.101286_bib53","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ t regulatory cells","volume":"109","author":"Curti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib54","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood-2008-07-144485","article-title":"The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology","volume":"113","author":"Curti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2019-123711","article-title":"Updated results from the venetoclax (Ven) in combination with idasanutlin (Idasa) arm of a phase 1b trial in elderly patients (Pts) with relapsed or refractory (R\/R) AML ineligible for cytotoxic chemotherapy","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in Relapsed\/Refractory acute myeloid leukemia: a nonrandomized, Open-Label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2022-158030","article-title":"Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in High-Risk patients with Relapsed\/Refractory acute myeloid leukemia (AML)","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib59","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib60","first-page":"1343","article-title":"A phase I study of FLX925, a dual FLT3 and CDK4\/6 inhibitor in patients with relapsed or refractory acute myeloid leukemia (AML)","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2025.101286_bib63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib64","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR t cell therapy in b cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.drup.2025.101286_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dnarep.2014.02.020","article-title":"DNA-PK: a dynamic enzyme in a versatile DSB repair pathway","volume":"17","author":"Davis","year":"2014","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.drup.2025.101286_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"'Acute myeloid leukemia: a comprehensive review and 2016 update'","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2025.101286_bib68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates t cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101286_bib69","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.drup.2025.101286_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2025.101286_bib71","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH annual meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib74","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-Mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2025.101286_bib75","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision Medicine for AML","volume":"18","author":"Dohner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib77","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2025.101286_bib78","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/76877","article-title":"The immunological synapse and the actin cytoskeleton: molecular hardware for t cell signaling","volume":"1","author":"Dustin","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1568-7864(02)00235-5","article-title":"Cleavage of cellular DNA by calicheamicin gamma1","volume":"2","author":"Elmroth","year":"2003","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.drup.2025.101286_bib81","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101286_bib82","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107564","article-title":"Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3(mut) acute myeloid leukemia","volume":"145","author":"Fu","year":"2024","journal-title":"Leuk. Res"},{"key":"10.1016\/j.drup.2025.101286_bib84","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2025.101286_bib85","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/cas.13324","article-title":"CD155, an onco-immunologic molecule in human tumors","volume":"108","author":"Gao","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2025.101286_bib86","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40291-021-00537-3","article-title":"IDH inhibitors and beyond: the cornerstone of targeted glioma treatment","volume":"25","author":"Gatto","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.drup.2025.101286_bib87","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150927","article-title":"The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-Directed gemtuzumab ozogamicin","volume":"138","author":"Gbadamosi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib88","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41375-022-01536-x","article-title":"In vivo anti-tumor effect of PARP inhibition in IDH1\/2 mutant MDS\/AML resistant to targeted inhibitors of mutant IDH1\/2","volume":"36","author":"Gbyli","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib89","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.drup.2025.101286_bib90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.16358","article-title":"Checkpoint inhibitors in AML: are we there yet?","volume":"188","author":"Ghosh","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib91","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.drup.2025.101286_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.882531","article-title":"Centurion and A. Mosquera orgueira, immune checkpoint inhibitors in acute myeloid leukemia: a Meta-Analysis","volume":"12","author":"Gomez-Llobell","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib93","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/0008-5472.CAN-14-0772-T","article-title":"IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism","volume":"74","author":"Grassian","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2025.101286_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for Venetoclax-Based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2025.101286_bib96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib97","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","article-title":"Deficient activation of bak and bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML","volume":"37","author":"Haag","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib98","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib99","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/368643a0","article-title":"Ligand for FLT3\/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs","volume":"368","author":"Hannum","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101286_bib100","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib101","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782065","article-title":"LY294002 is a promising inhibitor to overcome sorafenib resistance in FLT3-ITD mutant AML cells by interfering with PI3K\/Akt signaling pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2141.2004.05145.x","article-title":"The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors","volume":"127","author":"Hunter","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib104","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1517\/14712598.2011.604630","article-title":"Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia","volume":"11","author":"Hutter","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2025.101286_bib105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/14756366.2021.2020772","article-title":"Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants","volume":"37","author":"Im","year":"2022","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"10.1016\/j.drup.2025.101286_bib106","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101286_bib107","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","article-title":"Targeting hedgehog in hematologic malignancy","volume":"119","author":"Irvine","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib108","article-title":"Menin inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib109","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib110","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib111","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib112","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","article-title":"AI in small-molecule drug discovery: a coming wave?","volume":"21","author":"Jayatunga","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2025.101286_bib113","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","article-title":"FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"26","author":"Jen","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib114","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41375-023-01897-x","article-title":"FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4\/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML","volume":"37","author":"Jia","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib116","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1172\/JCI127907","article-title":"Targeting AML-associated FLT3 mutations with a type I kinase inhibitor","volume":"130","author":"Jones","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2025.101286_bib117","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib118","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib119","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus Low-Dose cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2025.101286_bib121","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib122","article-title":"CXCR4 inhibition enhances efficacy of FLT3 inhibitors in FLT3-Mutated AML augmented by suppressed TGF-b signaling","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2025.101286_bib123","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of t regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drup.2025.101286_bib124","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2025.101286_bib125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector t cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib126","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib127","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib128","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib129","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ t cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PPO.0000000000000570","article-title":"Combining isocitrate dehydrogenase inhibitors with existing regimens in acute myeloid leukemia: an evolving treatment landscape","volume":"28","author":"Lachowiez","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.drup.2025.101286_bib131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib132","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with High-Risk disease characteristics in childhood acute myeloid leukemia: a report from the children's oncology group","volume":"40","author":"Lamble","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib133","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev."},{"key":"10.1016\/j.drup.2025.101286_bib134","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood t cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib135","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/bloodadvances.2023010619","article-title":"A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia","volume":"8","author":"Levis","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib136","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib137","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/bcp.14022","article-title":"Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite","volume":"85","author":"Li","year":"2019","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.drup.2025.101286_bib138","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1038\/s41598-021-88120-y","article-title":"IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen","volume":"11","author":"Libura","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2025.101286_bib139","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2025.101286_bib140","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101286_bib141","article-title":"Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2","volume":"299","author":"Liu","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2025.101286_bib142","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.2019003538","article-title":"FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia","volume":"135","author":"Long","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib143","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-11-2939","article-title":"Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment","volume":"18","author":"Lu","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib144","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101286_bib145","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Lubbert","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib146","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.arcmed.2020.02.005","article-title":"CpG oligodeoxynucleotides induces apoptosis of human bladder cancer cells via Caspase-3-Bax\/Bcl-2-p53 axis","volume":"51","author":"Luo","year":"2020","journal-title":"Arch. Med Res"},{"key":"10.1016\/j.drup.2025.101286_bib147","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-21-1661","article-title":"Disabling uncompetitive inhibition of oncogenic IDH mutations drives acquired resistance","volume":"13","author":"Lyu","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101195","article-title":"Research progress on gene mutations and drug resistance in leukemia","volume":"79","author":"Ma","year":"2025","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101286_bib149","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bbrc.2018.08.068","article-title":"Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2","volume":"503","author":"Ma","year":"2018","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.drup.2025.101286_bib150","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-Mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib151","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib152","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2025.101286_bib153","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.drup.2025.101286_bib154","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR t cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating t cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"8","key":"10.1016\/j.drup.2025.101286_bib156","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drup.2025.101286_bib157","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10585-022-10189-0","article-title":"Resistance to targeted therapies in acute myeloid leukemia","volume":"40","author":"Mecklenbrauck","year":"2023","journal-title":"Clin. Exp. Metastas.."},{"key":"10.1016\/j.drup.2025.101286_bib158","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8828","article-title":"Overcoming adaptive therapy resistance in AML by targeting immune response pathways","volume":"11","author":"Melgar","year":"2019","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.drup.2025.101286_bib159","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.21723","article-title":"Sequence of administration and methylation of SOCS3 May govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)","volume":"85","author":"Middeldorf","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib160","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/bloodadvances.2020003554","article-title":"CAR t cells better than BiTEs","volume":"5","author":"Molina","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib161","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/jcb.20080","article-title":"Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target","volume":"92","author":"Monks","year":"2004","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.drup.2025.101286_bib162","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib163","doi-asserted-by":"crossref","first-page":"427","DOI":"10.23736\/S0026-4806.20.06989-X","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives","volume":"111","author":"Mosquera Orgueira","year":"2020","journal-title":"Minerva Med"},{"key":"10.1016\/j.drup.2025.101286_bib164","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib166","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: are we there yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.drup.2025.101286_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.drup.2025.101286_bib168","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100689","article-title":"Strategies to reduce the On-Target platelet toxicity of Bcl-x(L) inhibitors: PROTACs, SNIPERs and Prodrug-Based approaches","volume":"23","author":"Negi","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.drup.2025.101286_bib170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations","volume":"3","author":"Nelson","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib171","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101286_bib172","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101286_bib173","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.drup.2025.101286_bib174","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib175","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.drup.2025.101286_bib176","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006007","article-title":"Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling","volume":"7","author":"Oltvai","year":"2021","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.drup.2025.101286_bib177","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drup.2025.101286_bib178","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2006-05-023556","article-title":"CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover","volume":"109","author":"Orr","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib179","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(23)00207-7","article-title":"Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study","volume":"10","author":"Pabst","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib180","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib181","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101286_bib182","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","article-title":"The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients","volume":"26","author":"Pagano","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101286_bib183","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101286_bib184","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5045\/br.2020.55.1.17","article-title":"Characteristics of DNMT3A mutations in acute myeloid leukemia","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.drup.2025.101286_bib186","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/leu.2015.147","article-title":"Receptor tyrosine kinase axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia","volume":"29","author":"Park","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib187","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V128.22.1069.1069","article-title":"Final results of the chrysalis trial: a First-in-Human phase 1\/2 Dose-Escalation, Dose-Expansion study of gilteritinib (ASP2215) in patients with Relapsed\/Refractory acute myeloid leukemia (R\/R AML)","volume":"128","author":"Perl","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib188","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1535-7163.MCT-12-0129","article-title":"Breakdown of the FLT3-ITD\/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors","volume":"11","author":"Pietschmann","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101286_bib189","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib190","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130427","article-title":"Addition of the PARP inhibitor, talazoparib, to gemtuzumab ozogamicin significantly enhances Anti-Leukemic activity in human CD33+ acute myeloid leukemia","volume":"134","author":"Portwood","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib191","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1038\/sj.onc.1207196","article-title":"Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner","volume":"22","author":"Prokop","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101286_bib192","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101286_bib193","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib194","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13872","article-title":"The immune checkpoints cytotoxic t lymphocyte antigen-4 and lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia","volume":"96","author":"Radwan","year":"2020","journal-title":"HLA"},{"key":"10.1016\/j.drup.2025.101286_bib195","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1182\/blood-2011-09-378141","article-title":"Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process","volume":"119","author":"Rahmani","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061359","article-title":"2-Hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies","volume":"10","author":"Raimondi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2025.101286_bib197","doi-asserted-by":"crossref","unstructured":"F. Ravandi, R.B. Walter, M. Subklewe, V. Buecklein and A.S.J.J.o.C.O. Stein, Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML), 38 (2020), pp. 7508-7508.","DOI":"10.1200\/JCO.2020.38.15_suppl.7508"},{"key":"10.1016\/j.drup.2025.101286_bib198","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41577-021-00575-2","article-title":"Exhausted t cells never fully recover","volume":"21","author":"Reid","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib199","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in Immune-Based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib200","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.drup.2025.101286_bib201","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2025.101286_bib202","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.drup.2025.101286_bib203","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150371","article-title":"Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; an Open-Label, multicenter, phase 1b study","volume":"138","author":"Roboz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053518","article-title":"AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin","volume":"8","author":"Rosen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2025.101286_bib205","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib206","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"Don't eat me\" signal of CD47-SIRPalpha in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.drup.2025.101286_bib207","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 inhibitors, present and future","volume":"25","author":"Ryan","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.drup.2025.101286_bib208","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccell.2020.05.014","article-title":"Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia","volume":"38","author":"Salik","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib209","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2021-153286","article-title":"Long term Follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients","volume":"90","author":"Sanchez-Correa","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.drup.2025.101286_bib211","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib212","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib213","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR t cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib214","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib215","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib216","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib217","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"And A.M.L.S.G. For the German-Austrian, differential impact of allelic ratio and insertion site in FLT3-ITD\u2013positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.drup.2025.101286_bib218","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib219","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.drup.2025.101286_bib220","unstructured":"SEER, SEER data base: Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). Accessed August 15 2022. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009. (2022)."},{"key":"10.1016\/j.drup.2025.101286_bib221","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib222","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.drup.2025.101286_bib223","article-title":"Isocitrate dehydrogenase mutations in gliomas: a review of current understanding and trials","volume":"5","author":"Sharma","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.drup.2025.101286_bib224","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2025.101286_bib225","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2025.101286_bib226","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2025.101286_bib227","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2025.101286_bib228","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib229","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the Quizartinib-Resistant FLT3 \"gatekeeper\" F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib230","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120128","article-title":"Assembly of lung progenitors into developmentally-inspired geometry drives differentiation via cellular tension","volume":"254","author":"Soleas","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.drup.2025.101286_bib232","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00335-018-9770-7","article-title":"Interaction of PVR\/PVRL2 with TIGIT\/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer","volume":"29","author":"Stamm","year":"2018","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.drup.2025.101286_bib233","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib234","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41375-022-01751-6","article-title":"Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)","volume":"37","author":"Steinhauser","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib236","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib237","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib238","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2025.101286_bib239","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.drup.2025.101286_bib240","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR t cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2025.101286_bib241","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib242","article-title":"The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with&xa0;FLT3-ITD mutated myeloid leukemias: interim report of a Phase&xa0;I\/II trial, clinical lymphoma","volume":"17","author":"Swaminathan","year":"2017","journal-title":"Myeloma Leuk."},{"key":"10.1016\/j.drup.2025.101286_bib243","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased frequency and suppression by regulatory t cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib246","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib247","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-013-1365-1","article-title":"Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia","volume":"97","author":"Takeshita","year":"2013","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib248","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/annonc\/mdz006","article-title":"The macrophage 'do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target","volume":"30","author":"Takimoto","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib249","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor t cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med"},{"key":"10.1016\/j.drup.2025.101286_bib250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib251","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib252","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nbt.2488","article-title":"A community-driven global reconstruction of human metabolism","volume":"31","author":"Thiele","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2025.101286_bib253","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib254","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1517\/14712598.2014.922534","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia revisited","volume":"14","author":"Thol","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2025.101286_bib255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2025.101286_bib256","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib257","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat. Genet"},{"key":"10.1016\/j.drup.2025.101286_bib258","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.stemcr.2020.05.013","article-title":"Chromatin complexes maintain Self-Renewal of myeloid progenitors in AML: opportunities for therapeutic intervention","volume":"15","author":"Uckelmann","year":"2020","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.drup.2025.101286_bib259","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib260","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2025.101286_bib261","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2025.101286_bib262","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1443.011","article-title":"Basic and clinical immunology of siglecs","volume":"1143","author":"von Gunten","year":"2008","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.drup.2025.101286_bib263","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.drup.2025.101286_bib264","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.12640","article-title":"CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML","volume":"14","author":"Waldeck","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib265","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib266","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib267","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.drup.2025.101286_bib268","article-title":"One stone, two birds: the roles of Tim-3 in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.drup.2025.101286_bib269","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of t cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drup.2025.101286_bib270","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib271","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101286_bib272","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.drup.2025.101286_bib273","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib274","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified t cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2025.101286_bib275","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered t cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib276","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101286_bib277","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib278","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","article-title":"Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib279","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2012.96","article-title":"Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib\/multi-targeted inhibitors and JAK inhibitors","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib280","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib281","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719860645","article-title":"Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches","volume":"10","author":"Winer","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.drup.2025.101286_bib282","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.drup.2025.101286_bib284","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI39964","article-title":"Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia","volume":"120","author":"Xiang","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2025.101286_bib285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101286_bib286","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/leu.2016.297","article-title":"MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia","volume":"31","author":"Xu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2025.101286_bib287","first-page":"5487","article-title":"Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells","volume":"34","author":"Yamauchi","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib288","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib289","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drup.2025.101286_bib290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib291","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13046-021-02054-x","article-title":"Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers","volume":"40","author":"Yao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib292","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215603","article-title":"Resistance to mutant IDH inhibitors in acute myeloid leukemia: molecular mechanisms and therapeutic strategies","volume":"533","author":"Yao","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101286_bib293","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153426","article-title":"Quizartinib (Quiz) with decitabine (DAC) and venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) - RAS\/MAPK mutations continue to drive primary and secondary resistance","volume":"138","author":"Yilmaz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib294","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2021-153426","article-title":"Quizartinib (Quiz) with decitabine (DAC) and venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) - RAS\/MAPK mutations continue to drive primary and secondary resistance","volume":"138","author":"Yilmaz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib295","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.46593","article-title":"LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia","volume":"11","author":"Yu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2025.101286_bib296","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2025.101286_bib297","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res"},{"key":"10.1016\/j.drup.2025.101286_bib298","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib299","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after High-Dose cytarabine in Relapsed\/Refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.drup.2025.101286_bib300","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.drup.2025.101286_bib301","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2025.101286_bib302","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101286_bib303","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","article-title":"The dual MEK\/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring Resistance-Conferring FLT3 mutations","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101286_bib304","first-page":"675","article-title":"FLT3 and CDK4\/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia","volume":"41","author":"Zhang","year":"2014","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.drup.2025.101286_bib305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.drup.2025.101286_bib306","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.32534","article-title":"Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib307","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2025.101286_bib308","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101286_bib309","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2025.101286_bib310","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejmech.2018.06.010","article-title":"Discovery of the selective and efficacious inhibitors of FLT3 mutations","volume":"155","author":"Zhi","year":"2018","journal-title":"Eur. J. Med Chem."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:21:53Z","timestamp":1772886113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":310,"alternative-id":["S1368764625000895"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101286","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101286"}}